Pharmaceuticals News and Research

RSS

Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment

NovaBay Pharmaceuticals, Inc. announced today that its development partner, Alcon Research, Ltd., has concluded its proof of concept clinical trial of NovaBay's patented lead Aganocide compound, NVC-422 for the treatment of viral conjunctivitis a highly contagious eye infection for which there are currently no marketed products.

18 Oct 2010

Bend Research extends 3-year agreement with Bristol-Myers Squibb

Bend Research Inc. a leading independent technology-based drug-formulation development and manufacturing organization, announced today it has extended its drug discovery enablement and development services agreement with Bristol-Myers Squibb Company, a global biopharmaceutical company.

18 Oct 2010

ACR Image Metrix hosted Novel Medical Imaging Approaches for Early Drug Development event

ACR Image Metrix, a global imaging contract research organization (CRO) with expertise in imaging trial design, techniques and data extraction, hosted the Novel Medical Imaging Approaches for Early Drug Development Methods, Technical Issues and Case Studies event, which took place at the Boston Marriott Cambridge, in Cambridge Massachusetts, on September 16, 2010.

18 Oct 2010

Bioniche's research scientists give presentations at Modern Vaccine and Adjuvant Formulation Conference

Bioniche Life Sciences Inc. a research-based, technology driven Canadian biopharmaceutical company, today announced that two of its senior research scientists gave presentations at the Modern Vaccine and Adjuvant Formulation Conference in Cannes, France this week.

18 Oct 2010

Shrink reveals image of StemDisc450 biomedical research tool

Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed an image of its first product offering the StemDisc450, a high-yield, low cost, patent-pending cell culturing biomedical research tool.

18 Oct 2010

Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver

Cempra Pharmaceuticals today announced poster presentations on its novel fluoroketolide antibiotic, solithromycin (CEM-101), and the Company's proprietary front-loading oral dosing regimen of sodium fusidate, TAKSTA (CEM-102) at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia.

18 Oct 2010

UK Intellectual Property Office issues patent for entinostat

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced the UK Intellectual Property Office allowed application GB0907347.9 entitled N-(2-aminophenyl)-4-[N-(pyridine-3-YL)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B.

18 Oct 2010

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis. The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

18 Oct 2010

FDA approves ISTA's sNDA for BROMDAY ophthalmic anti-inflammatory drug

ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.

18 Oct 2010

Teva Pharmaceutical announces new data from PreCISe study

Teva Pharmaceutical Industries Ltd. today announced new data from the five-year extension of the PreCISe study demonstrating that earlier initiation of treatment with Copaxone (glatiramer acetate injection) in patients presenting with first signs of multiple sclerosis (MS), provided greater effects in delaying conversion to clinically definite MS (CDMS) compared to later treatment initiation after diagnosis of CDMS or after three years on the study.

18 Oct 2010

New analysis examines guiding principles for policymakers to fight health care fraud

In light of the recent historic Medicare fraud bust, a new analysis that examines the "Seven Guiding Principles for Policymakers" to fighting health care fraud invites new questions about legislative efforts to reduce accountability and oversight of independent pharmacies, the Pharmaceutical Care Management Association (PCMA) said today.

15 Oct 2010

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that data providing further evidence of the neuroprotective properties of laquinimod in animal studies were presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

15 Oct 2010

TPG Growth acquires 25% of Schiff Nutrition's fully diluted outstanding shares from WHF

Schiff Nutrition International, Inc., announced today that TPG Growth, the middle market buyout and growth platform of TPG, a global private investment firm, has purchased approximately 25% of Schiff Nutrition's fully diluted outstanding shares from Weider Health and Fitness (WHF), Schiff Nutrition's majority shareholder, for $48.8 million.

15 Oct 2010

Oragenics to feature ProBiora3 oral care probiotic ingredient at Supply Side West

Florida-based biopharmaceutical company Oragenics, Inc. announced that it will feature the company's ProBiora3® oral care probiotic ingredient at Supply Side West, October 19 - 23, 2010 in Las Vegas, NV.

15 Oct 2010

Anadys prices underwritten public offering of common stock

Anadys Pharmaceuticals, Inc. announced today the pricing of its underwritten public offering of 13,888,889 shares of its common stock at a price to the public of $1.80 per share. The gross proceeds to Anadys from this offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

15 Oct 2010

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Questcor Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Questcor's supplemental new drug application (sNDA) for H.P. Acthar® Gel (repository corticotropin injection) in the treatment of infantile spasms (IS), an ultra-rare orphan disorder affecting approximately 2,000 American children annually. IS is a devastating and potentially life-threatening form of epilepsy seen in infancy and early childhood.

15 Oct 2010

VWR moves to new corporate headquarters in Radnor, PA

VWR International, LLC today celebrates the official grand opening of its new corporate headquarters at the Radnor Corporate Center in Radnor, PA. The new facility not only preserves jobs in the state and region, but also offers the opportunity for increased staffing as the company grows.

15 Oct 2010

Access receives first MuGard prescriptions and reimbursement

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.

15 Oct 2010

Watson Laboratories receives FDA approval for Amlodipine capsules

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Amlodipine Besylate/Benazepril 5/20mg, 10/20mg, 2.5/10mg, and 5/10mg capsules, the generic equivalent to Novartis' Lotrel capsules.

15 Oct 2010

NovaBay to present two poster presentations at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that it will deliver two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA).

15 Oct 2010

Pharmaceuticals News and Research

Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment

Bend Research extends 3-year agreement with Bristol-Myers Squibb

ACR Image Metrix hosted Novel Medical Imaging Approaches for Early Drug Development event

Bioniche's research scientists give presentations at Modern Vaccine and Adjuvant Formulation Conference

Shrink reveals image of StemDisc450 biomedical research tool

Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver

UK Intellectual Property Office issues patent for entinostat

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

FDA approves ISTA's sNDA for BROMDAY ophthalmic anti-inflammatory drug

Teva Pharmaceutical announces new data from PreCISe study

New analysis examines guiding principles for policymakers to fight health care fraud

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

TPG Growth acquires 25% of Schiff Nutrition's fully diluted outstanding shares from WHF

Oragenics to feature ProBiora3 oral care probiotic ingredient at Supply Side West

Anadys prices underwritten public offering of common stock

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

VWR moves to new corporate headquarters in Radnor, PA

Access receives first MuGard prescriptions and reimbursement

Watson Laboratories receives FDA approval for Amlodipine capsules

NovaBay to present two poster presentations at IDSA Annual Meeting

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence